Acarbose: Its role in the treatment of diabetes mellitus

Annals of Pharmacotherapy

Volumn 30, Issue 11, 1996, Pages 1255-1262

  Campbell, Lance K ^a   White, John R ^a   Campbell, R Keith ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG COST; DRUG EXCRETION; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; EXERCISE; GASTROINTESTINAL SYMPTOM; GOOD CLINICAL PRACTICE; HUMAN; HYPERGLYCEMIA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0029914136     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603001110     Document Type: Review

References (33)

1. Kowie CC, Eberhardt MS, eds. Diabetes 1996: vital statistics. Alexandria, VA: American Diabetes Association, 1996:1-102.
2. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
3. Investigator's brochure. Bay g 5421 (acarbose). West Haven, CT: Bayer Corporation, Pharmaceutical Division. Version 6, March 1995.
4. Nathan DM. Management of insulin-dependent diabetes mellitus. Drugs 1992;44(suppl 3):39-46.
5. Rios MS. Acarbose and insulin therapy in type I diabetes mellitus. Eur J Clin Invest 1994;24(suppl 3):36-9.
6. Marena S, Tagliaferro V, Cavallero G, Pagani A, Montegrosso G, Bianchi W, et al. Double-blind crossover study of acarbose in type I diabetic patients. Diabet Med 1991;8:674-8.
7. Bischoff H. Pharmacology of alpha-glucosidase inhibition. Eur J Clin Invest 1994;24(suppl 3):3-10.
8. Laube H, Federlin K, Hillebrand I. Effect of alpha-inhibitors on blood glucose and insulin levels. Adv Exp Med Biol 1988;246:287-93.
9. Goke B, Herrmann C, Goke R, Fehmann HC, Berghofer P, Richter G, et al. Intestinal effects of alpha-glucosidase inhibitors: absorption of nutrients and enterohormonal changes. Eur J Clin Invest 1994;24(suppl 3): 25-30.
10. Leonhart W, Hanefeld M, Fischer S, Schulze J. Efficacy of alpha-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia. Eur J Clin Invest 1994;24(suppl 3):45-9.
11. 14C)acarbose to rats, dogs and man. Arzneimittelforschung 1989;39:1254-60.
12. 14C)acarbose to rats and dogs. Arzneimittelforschung 1989;39:1261-7.
13. Zillikens MC, Swart GR, van den Berg JW, Wilson JH. Effects of the glucosidase inhibitor acarbose in patients with liver cirrhosis. Aliment Pharmacol Ther 1989;3:453-9.
14. Summary of the efficacy and safety of acarbose for the treatment of NIDDM patients maintained on diet alone or on diet plus sulfonylurea drugs. West Haven, CT: Pharmaceutical Division, Miles Inc., 1995.
15. Coniff RF, Shapiro JA, Seaton TB. Long term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med 1994;154:2442-8.
16. Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. Diabetes Care 1995;18:817-24.
17. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991;14:732-7.
18. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (Bay g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995;98:443-51.
19. Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, et al. The efficacy of acarbose in treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 1994;121:928-35.
20. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994;11:223-41.
21. Reuser AJJ, Wisselaar HA. An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus. Eur J Clin Invest 1994;24(suppl 3):19-24.
22. Hollander P. Safety profile of acarbose, an alpha-glucosidase inhibitor. Drugs 1992;44(suppl 2):47-53.
23. Van-Gall L, Nobels F, De Leeuw I. Effects of acarbose on carbohydrate metabolism, electrolytes, minerals and vitamins in fairly well-controlled non-insulin-dependent diabetes mellitus. Gastroenterology 1991;29:6424.
24. Toeller M. Nutritional recommendations for diabetic patients and treatment with alpha-glucosidase inhibitors. Drugs 1992;44(suppl 3):13-20.
25. Tuonilehto J, Pohjola M, Lindstrom J, Aro A. Acarbose and nutrient intake in non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 1994;26:215-22.
26. Scheen AJ, Lefebvre PJ. Antihyperglycaemic agents: drug interactions of clinical importance. Drug Saf 1995;12:32-45.
27. Scheen AJ, Ferreira Alves de Magalhaes AC, Salvatore T, Lefebvre PJ. Reduction of the acute bioavailability of metformin by the alpha-glucosidase inhibitor acarbose in normal man. Eur J Clin Invest 1994;24(suppl 3):50-4.
28. Package insert. Precose (acarbose). West Haven, CT: Bayer Corporation, Pharmaceutical Division, 1995.
29. Drug topics red book 1996. Montvale, NJ: Medical Economics, Inc., 1996.
30. Tattersall R. Alpha-glucosidase inhibition as an adjunct in the treatment of type II diabetes. Diabet Med 1993;10:688-93.
31. Clissold SP, Edwards C. Acarbose: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1988;35:214-43.
32. Richard JL, Rodier M, Monnier L, Orsetti A, Mirouze J. Effect of acarbose on glucose and insulin response to sucrose load in reactive hypoglycemia. Diabete Metab 1988;14:114-8.
33. McCulloch DK, Kurtz AB, Tattersall RB. A new approach to the treatment of nocturnal hypoglycemia using alpha-glucosidase inhibition. Diabetes Care 1983;6:483-7.